Clinical trial
Spironolactone Safety in Dialysis Patients
NCT00328809 · State University of New York - Upstate Medical University, Other · Withdrawn
Key facts
| NCT number | NCT00328809 |
|---|---|
| Title | Spironolactone Safety in Dialysis Patients |
| Official title | Subjects With Severe Heart Failure and End-Stage Renal Disease on Hemodialysis: A Pilot Study to Assess Safety and Tolerability of Spironolactone |
| Lead sponsor | State University of New York - Upstate Medical University, Other |
| Status | Withdrawn |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | End Stage Renal Disease, Congestive Heart Failure |
| Intervention type | Drug |
| Interventions | spironolactone |
| Enrollment | 0 |
| Start date | Jun 30, 2013 |
| Primary completion | Jun 30, 2017 |
| Completion | Sep 24, 2019 |
| First posted | May 22, 2006 |
| Last update posted | Oct 22, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: